P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1578
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC With High PD-L1 Expression Tested on Cytology Versus Biopsy Samples

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Pcp61 - Evidence-Based Value of Pd-1 / Pd-L1 Inhibitors in Nsclc: Comparison of Value to Price

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy